
    
      Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the
      Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by
      Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an
      Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects
      followed by an Optional 60-Week Treatment Extension Phase
    
  